Radiopharm Theranostics Ltd (RAD)

Snapshot

Announcements

Corporate Overview

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date	Amount	Franking	Gross	Type	Payable
No dividends paid.

Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Name	Title	Since	Bio
Mr Paul Alex Hopper	Executive Chairman,Executive Director,Founder	N/A	Mr Paul Alex Hopper Executive Chairman,Executive Director,Founder Mr Hopper has over 25 years experience in biotech, healthcare and life sciences with a focus on start-up and growth companies. He has served as either Founder, Chairman, non-executive director, or CEO, for more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers fund raising in Australia, Asia, US and Europe, and he has experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances. He is the Founder and Executive Chairman of ASX listed Imugene Limited (ASX:IMU). He licensed the technology from the University of Vienna Medical School in 2012 and listed the company on the ASX in December 2013. He is the Founder of Vaxinia and Chimeric Therapeutics Limited (ASX:CHM). In 2008, he became Chairman of ASX listed Viralytics Limited (ASX:VLA) and is also the Founder of Glioblast. Mr Hopper is also a Founder of ASX listed Prescient Therapeutics Limited.
Dr Michael Baker	Non-Executive Director	N/A	Dr Michael Baker Non-Executive Director Dr Baker is currently CEO and managing director of ASX listed Suda Pharmaceuticals which is developing technologies in the cell therapy and drug delivery fields. Prior to Suda he was an investment manager with Australian life science fund, BioScience Managers and a senior manager at Hexima Limited. He was awarded the Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering in 2010. Dr Baker was also the Alexander von Humbolt Research Fellow at the University of Cologne. He is also a risk management committee Chairperson.
Mr Ian Turner	Non-Executive Director	N/A	Mr Ian Turner Non-Executive Director Mr Turner is an experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a C-level career across some of the corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012, where he was recruited to turnaround Siemens underperforming global radiopharmacy lines. Prior to this, he was General Manager of ANSTO Radiopharmaceuticals in Sydney. He was also Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at Varian Inc based in Palo Alto and Melbourne. He was also previously a director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US. Mr Turner filed for voluntary bankruptcy and became bankrupt on 17 October 2016, consequential to the collapse of Timbercorp Limited and associated entities. Mr Turner was discharged from bankruptcy on 18 October 2019. He is also a member of risk management committee.
Mr Riccardo Canevari	Chief Executive Officer,Managing Director	N/A	Mr Riccardo Canevari Chief Executive Officer,Managing Director Mr Canevari has experience across specialty pharmaceuticals, oncology and radiopharmaceuticals. Most recently, he was the Chief Commercial Officer of Novartis company Advanced Accelerator Applications. He was responsible for global commercial strategy and country organisations in approximately 20 countries across North America, Europe and Asia. He assessed Go To Market Models for each priority country and access to other markets. Prior to this, he was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.
Mr Nathan Jong	Joint Company Secretary	N/A
Mr Phillip Hains	Chief Financial Officer,Joint Company Secretary	N/A

Show All

Director Interests

Director	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
Riccardo Canevari	N/A	N/A	N/A	N/A	N/A
Ian Turner	N/A	N/A	N/A	N/A	N/A
Michael Baker	N/A	N/A	N/A	N/A	N/A
Paul Hopper	N/A	N/A	N/A	N/A	N/A

Show All

Top 20 Shareholders

About the Data

Name	Shares	Capital
Kilnwata Investments Limited	90,000,000	35.53%
Nanomab Technologies Limited	21,111,111	8.33%
CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 A/C> (i)	9,862,888	3.89%
Merrill Lynch Australia Nominees Pty Limited <MLPro A/C>	6,666,667	2.63%
HSBC Custody Nominees	6,003,189	2.37%
Trimt GMBH	4,444,444	1.75%
HSBC Custody Nominees Australia Limited A/C 2	4,124,888	1.63%
Ricardo Canevari	4,000,000	1.58%
CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 A/C> (ii)	3,333,334	1.32%
Citicorp Nominees Pty Limited	3,315,687	1.31%
Brispot Nominees Pty Ltd <House Head Nominee A/C>	3,000,000	1.18%
Thorney Technologies Ltd	2,888,889	1.14%
Tiga Trading Pty Ltd	2,888,889	1.14%
Mr Richard John Mann	2,083,500	0.82%
Carnport Pty Limited	1,777,778	0.70%
Frazis Capital Partners	1,666,667	0.66%
J P Morgan Nominees Australia Pty Limited	1,666,667	0.66%
One Managed Investments Fund Ltd <Fifth Estate Emerging Companies A/C>	1,666,667	0.66%
Australian Direct Investment Pty Limited <Super Fund A/C>	1,334,167	0.53%
WACC Pty Ltd <Progressive Global A/C>	1,333,334	0.53%
UBS Nominees Pty Ltd	1,333,333	0.53%
National Nominees Limited	1,167,960	0.46%
Portfolio Nominees Pty Ltd	1,083,500	0.43%

Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Substantial Shareholders

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Share Price History

Date	Close	Change	%Chg	Open	High	Low	Volume	Turnover

Full Month

Historical Data

Year	Closing Price	Last Trade
No Financial Year End data available

RAD Historical Price Data (CSV)

Up to 20 years of EOD share price history

Sign up to Download

You must be logged in to access this feature. Please sign up for free or login.